13 October 2021
At the meeting of 8 September 2021 the RMA:
Determined Statements of Principles (SOPs) for:
| Condition | SOPs | |
|---|---|---|
| dental pulp and periapical disease | 99/2021 | 100/2021 |
| chronic gastritis and chronic gastropathy | 101/2021 | 102/2021 |
| malignant neoplasm of the pancreas | 103/2021 | 104/2021 |
These SOPs revoke the SOPs previously determined for these conditions.
The above SOPs take effect from 1 November 2021.
Summary of Changes
Decided to Undertake Consultation regarding:
| Condition | Reasons for Decision | Date for Final Decision |
|---|---|---|
| gingivitis | Intention to remove one or more factors | December 2021 |
| malignant neoplasm of the colon and rectum | Intention to remove one or more factors | December 2021 |
Completed Investigations
The above determinations conclude the previously advertised investigations into:
New Investigations
Decided to advertise the following investigations:
- exertional heat illness
- eosinophilic oesophagitis
- portal vein thrombosis
- hypopituitarism (focussed review - immune checkpoint inhibitors)
- hypogonadism (focussed review - immune checkpoint inhibitors)
- diabetes mellitus (focussed review - immune checkpoint inhibitors)
The above investigation notices appear in the Government Notices Gazette of 12 October 2021.